The Upjohn Manufacturing Company and the Upjohn Company v. Richard S. Schweiker, Secretary

PHILLIPS, Senior Circuit Judge. This appeal grew out of Food and Drug Administration (FDA) approval of a new drug application filed by a competitor of appellants Upjohn, Boots Pharmaceuticals, Inc. (Boots). In the new drug application, Boots sought permission to manufacture and distribute the drug ibuprofen under the trademark, “Rufen.” FDA had approved a new drug application submitted by Upjohn for ibuprofen in 1974. Upjohn had developed a substantial market for this drug under the name “Motrin.” This drug is prescribed for relief of osteoarthritis, rheumatoid arthritis and mild to moderate pain. Upjohn filed the present suit against the Secretary of Health and Human Services and the Commissioner of Food and Drugs, appellees, challenging the approval of Boots’ application as unlawful and seeking a declaratory judgment and injunctive relief. District Judge Benjamin F. Gibson granted the motion of defendants for summary judgment. Upjohn appeals. We affirm. Reference is made to the comprehensive opinion of Judge Gibson for a recitation of pertinent facts. Upjohn Manufacturing Co. v. Schweiker, 520 F.Supp. 58 (W.D.Mich.1981). I In 1961, a British corporation, the Boots Company, Ltd. (the parent of Boots Pharmaceuticals) synthesized the chemical ibuprofen and obtained patents for it in 45 countries, including the United States. In 1969, Upjohn purchased a nonexclusive license from the Boots Company, Ltd., to sell ibuprofen in the Western Hemisphere. Before Upjohn could market ibuprofen in the United States, it was required to obtain FDA approval of a new drug application. 21 U.S.C. § 355(a). A new drug application *482 must show with “full reports and investigations” that the drug is “safe ... and effective.” 21 U.S.C. § 355(b)(1). Upjohn states that it spent approximately $5 million in gaining FDA approval in 1974 to market ibuprofen for relief of the symptoms of osteoarthritis and rheumatoid arthritis. Later, Upjohn avers, it spent an additional $1 million and gained FDA approval to market ibuprofen tablets for relief of mild to moderate pain. As stated above, Upjohn markets the drug under the name “Motrin.” Upjohn’s investment proved to be profitable. Motrin is the leading drug in the arthritis prescription market. In 1981 Motrin accounted for one-third of Upjohn’s total profits. 1 Since Motrin was not a duplicate of a previously prescribed drug, Upjohn’s new drug application was what is known in the industry as a “pioneer NDA.” FDA generally requires an applicant for a pioneer NDA to verify the reports of clinical investigations by submitting the underlying or “raw” data upon which the investigations are based. When a company submits a new drug application for a duplicate of a previously approved drug, the application is known as a “duplicate NDA.” Although duplicate NDAs must meet the same statutory and regulatory requirements as pioneer NDAs, the FDA has adopted a policy of allowing the applicant for a duplicate NDA to rely on published scientific reports. The applicant is not required to submit the “raw” data upon which these reports are based. This policy, known as the “paper NDA” policy, 2 allows a manufacturer of an exact duplicate of a previously approved drug to get approval to market the drug without performing duplicative clinical testing. Boots submitted a new drug application which later was approved by FDA under its “paper NDA” policy. Upjohn filed a “citizen petition” with FDA pursuant to 21 C.F.R. § 10.30 and urged denial of the Boots application. Upjohn asserted that any FDA approval of the Boots paper NDA would consciously or unconsciously rely on the raw data supporting the Upjohn pioneer NDA, and that such reliance would violate FDA regulations and 21 U.S.C. § 331(j) which classify the raw data as nondisclosa-ble trade secrets. FDA denied the Upjohn petition and approved the Boots application. II In its complaint, filed in the district court, Upjohn alleged FDA could not have approved Boots’ application without relying on trade secret raw data contained in the earlier Upjohn pioneer application for permission to market the same drug. Upjohn asserted that reliance on that data violated the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301, et seq. and the FDA regulations promulgated thereunder. Upjohn also alleged that FDA’s actions violated the Administrative Procedure Act, 5 U.S.C. § 551 et seq. because the actions were “unreasonable, arbitrary, capricious, an abuse of discretion, and otherwise unlawful.” Judge Gibson restricted his review of FDA’s actions to the administrative record before him. That record consisted of the documents contained in the Upjohn citizen petition and the “Summary Basis of Approval” 3 of the Boots application. *483 Since this suit was brought pursuant to the provisions of the Administrative Procedure Act for review of a final agency action, the challenged FDA decision may be set aside only if “arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law,” 5 U.S.C. § 706(2)(A), or “unwarranted by the facts to the extent that the facts are subject to trial de novo by the reviewing court,” 5 U.S.C. § 706(2)(F). Upjohn argues that this is a case in which the “facts are subject to a trial de novo” and that the district court erred in restricting its review to the administrative record. Upjohn contends that, before granting the motion of defendant for summary judgment, the district court should have considered certain affidavits submitted by Upjohn. The affidavits attacked the reports and information supporting the Boots application, but were not part of the administrative record compiled by the FDA. When de novo review of agency action is not expressly required by statute, it is the exception rather than the rule. United States v. Cario Bianchi & Co., 373 U.S. 709, 715, 83 S.Ct. 1409, 1413, 10 L.Ed.2d 652 (1963) “[D]e novo review is appropriate only where there are inadequate factfinding procedures in an adjudicatory proceeding, or where judicial proceedings are brought to enforce certain administrative actions.” Camp v. Pitts, 411 U.S. 138, 142, 93 S.Ct. 1241, 1244, 36 L.Ed.2d 106 (1973). See also Doraiswamy v. Secretary of Labor, 555 F.2d 832, 839-42 (D.C.Cir.1976) (collecting cases). We do not find the factfinding procedures employed by FDA in approving the Boots NDA and rejecting the Upjohn petition to be inadequate. FDA followed the applicable statutory and regulatory criteria for approving new drug applications. See 21 U.S.C. § 355(d); 21 C.F.R. § 314.1. During the two and one-half years which elapsed between the submission of the Boots application and approval by FDA of that application, FDA gathered considerable evidence with respect to the safety and effectiveness of ibuprofen. Although these factfinding procedures were informal, we do not agree with the assertion by Upjohn that all informal factfinding procedures, no matter how complex and detailed, are inadequate in the sense that they are subject to de novo review. See Camp v. Pitts, supra, 411 U.S. at 142, 93 S.Ct. at 1244; Citizens to Preserve Overton Park v. Volpe, 401 U.S. 402, 415, 91 S.Ct. 814, 823, 28 L.Ed.2d 136 (1971); Doraiswamy v. Secretary of Labor, supra, 555 F.2d 832, 840. It is to be emphasized that Upjohn did not file with FDA the affidavits which it now contends should have been considered by the district court. Upjohn could have filed a petition for reconsideration of FDA’s approval of the Boots application. 21 C.F.R. § 10.33. By that procedure the affidavits could have been submitted to FDA and made a part of the administrative record for judicial review. Instead, Upjohn chose to present the affidavits for the first time in the district court. Upjohn also argues that the district court erred in refusing to go outside the administrative record because FDA’s explanation of its actions was inadequate, relying upon Citizens to Preserve Overton Park v. Volpe, supra, 401 U.S. at 420, 91 S.Ct. at 825. We do not find the explanation by the agency to be inadequate. To the contrary, FDA stated in detail the grounds for its decision and the essential facts upon which the decision was based. Nothing more is required. See Dunlop v. Bachowski, 421 U.S. 560, 572-74, 95 S.Ct. 1851, 1860, 44 L.Ed.2d 377 (1975). Ill Once efforts by Upjohn to supplement the administrative record were rejected, summary judgment became an appropriate manner for the district court to dispose of the controversy. Milton v. Harris, 616 F.2d 968, 975-76 (7th Cir. 1980); Doraiswamy, supra, 555 F.2d 832, 836; Richards v. INS, 554 F.2d 1173, 1177, n.28 (D.C.Cir.1977). We agree with the district court that there is no evidence in the administrative record to support Upjohn’s contentions that FDA acted arbitrarily or capriciously or abused its discretion. Moreover, we find *484 no evidence in the record, other than con-clusory allegations by Upjohn, that FDA relied upon Upjohn’s trade secret data in approving Boots’ application. IV Upjohn further contends that FDA arbitrarily applied different standards in approving the Boots and Upjohn new drug applications. This is little more than an attack upon the “paper NDA” policy of FDA, although Upjohn states that it does not attack the “paper NDA” policy in these proceedings. Boots and Upjohn were required to meet the same statutory criteria in support of their respective applications. Although there was a difference in the types of information each was required to submit, this disparity in treatment is inherent in FDA’s “paper NDA” policy. Under this policy there is a difference in the position of the party submitting a pioneer new drug application and the party submitting a duplicate new drug application. At the time Boots’ duplicate new drug application was submitted, the FDA had acquired considerable additional information about ibuprofen through market experience which was not available at the time Upjohn filed its pioneer application. Almost all credible published reports indicate that ibuprofen is safe and effective. The record indicates that market experience with the drug supports the conclusions contained in the reports. Of course Upjohn does not contend that the drug is not safe and effective. Instead, it has mounted a technical assault on FDA’s approval of the Boots application, in an effort to preserve its monopoly. The Federal Food, Drug and Cosmetic Act and the underlying regulations governing the approval for the marketing of new drugs were not intended to provide patent-like protection for a seller who has gained approval of a pioneer new drug application. It is to be emphasized that the patent to ibuprofen is owned by the parent corporation of Boots Pharmaceuticals. Upjohn has only a non-exclusive license from the owner of the patent to sell the drug in the Western Hemisphere. All other contentions of Upjohn have been considered and found to be without merit. For the reasons stated above and in the comprehensive opinion of the district court, 520 F.Supp. 58, the judgment of the district court is affirmed. No costs are taxed. The parties will bear their own costs on this appeal. Footnotes [1] New York Times, April 23, 1982, at page 32, column 6. [2] A statement of the “paper NDA” policy is published at 46 Fed.Reg. 27396 (May 19, 1981), and the reasoning underlying the policy may be found at 45 Fed.Reg. 82052-82063 (Dec. 12, 1980). The adoption by FDA of the “paper NDA” policy created considerable controversy. Allegations that the policy is illegal were rejected, however, in Burroughs Wellcome Co. v. Schweiker, 649 F.2d 221 (4th Cir. 1981). Upjohn opposed the “paper NDA” policy as ami-cus curiae in Burroughs Wellcome, but does not challenge the “paper NDA” policy in this litigation. [3] The “Summary Basis of Approval” is a summary of the data and information used to support the application, and is the essential information upon which the FDA based its approval. See 21 C.F.R. 314.14(e)(2).